The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.

A "systems medicine" approach to the study of non-alcoholic fatty liver disease / Petta, S; Valenti, L; Bugianesi, E; Targher, G; Bellentani, S; Bonino, F; Nobili, V. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 48:3(2016), pp. 333-342. [10.1016/j.dld.2015.10.027]

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

Petta S;Bonino F;nobili v
2016

Abstract

The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.
2016
Fatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Hepatology; Gastroenterology
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
A "systems medicine" approach to the study of non-alcoholic fatty liver disease / Petta, S; Valenti, L; Bugianesi, E; Targher, G; Bellentani, S; Bonino, F; Nobili, V. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 48:3(2016), pp. 333-342. [10.1016/j.dld.2015.10.027]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1177762
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 51
social impact